October 23, 2016 2:05 PM ET


Company Overview of Parion Sciences, Inc.

Company Overview

Parion Sciences, Inc. is engaged in the research, development, and commercialization of treatments to restore patient’s innate mucosal surface defenses. Its pipeline includes P-1037, a clinical stage ENaC blocker for pulmonary disease and cystic fibrosis; tPAD, a trans-nasal pulmonary aerosol delivery system for inhaled drug delivery for cystic fibrosis; mucolytic agents for respiratory diseases; Parion CFTR corrector program for cystic fibrosis; and P-321 for dry eye disease. The company was formerly known as CyFi, Inc. and changed its name to Parion Sciences, Inc. in October 2002. Parion Sciences, Inc. was founded in 1999 and is based in Durham, North Carolina.

2800 Meridian Parkway

Suite 195

Durham, NC 27713

United States

Founded in 1999





Key Executives for Parion Sciences, Inc.

Chief Executive Officer, President and Director
Co-Founder and Co-Chairman
Age: 71
Co-Founder and Co-Chairman
Chief Operating Officer
Age: 51
Executive Director of Clinical & Regulatory Operations
Compensation as of Fiscal Year 2016.

Parion Sciences, Inc. Key Developments

Parion Sciences Announces Initiation of Phase 2 Clinical Trial of P-321 for the Treatment of Dry Eye Disease

Parion Sciences announced that it has initiated a phase 2 clinical trial of P-321 Ophthalmic Solution in patients with Dry Eye Disease (DED). P-321 is a potent inhibitor of the epithelial sodium channels (ENaC) on the ocular surface, and is expected to restore the tear film on the ocular surface in those patients with dry eye disease. Earlier this year the results of a Phase 1/2a safety, tolerability, and pharmacokinetics study in subjects with dry eye were presented. Below is additional information on the new trial: Study P-321-202 is an assessment of the impact of P-321 on dry eye symptoms as well as clinical signs of dry eye disease and safety. Parion expects to enroll approximately 60 patients in the randomized, double-masked, parallel group study of P-321 Ophthalmic Solution compared to placebo in patients with dry eye disease over 28 Days. The purpose of this study is to evaluate the effect of treatment with P-321 Ophthalmic Solution on dry eye symptoms. Patient enrollment has begun and the first patient has been enrolled in the trial.

Parion Sciences, Inc. Presents at SunTrust Robinson Humphrey's 2016 Orphan Drug Day, Feb-23-2016

Parion Sciences, Inc. Presents at SunTrust Robinson Humphrey's 2016 Orphan Drug Day, Feb-23-2016 . Venue: JW Marriott Essex House, 160 Central Park South (b/w 58th & 59th Street), New York, NY 10019, United States.

Ceva and Zoion Pharma Announce Collaboration to Develop Epithelial Sodium Channel Blockers to Treat Veterinary Ocular Surface Diseases

Ceva Sant Animale and Zoion Pharma Inc. announced that they have entered into a collaboration to develop an epithelial sodium channel (ENaC) inhibitor to treat veterinary ocular surface diseases characterized by a lack of surface hydration, such as keratoconjunctivitis sicca (KCS) commonly called dry eye. Under the agreement, Ceva gains worldwide development and commercial rights to ZP-1 (P-1046). ZP-1 has successfully completed a proof-of-concept clinical trial in canine KCS. ZP-1 (P-1046) was originally discovered by Parion Sciences, Inc. and licensed to Zoion Pharma for veterinary use. Financial terms of the collaboration were not disclosed.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Parion Sciences, Inc., please visit www.parion.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.